Literature DB >> 1409196

Mitral stenosis in the Maroteaux-Lamy syndrome: a treatable cause of dyspnoea.

T H Marwick1, B Bastian, C F Hughes, B P Bailey.   

Abstract

The case is reported of a young woman with the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI) who presented with rapidly progressive dyspnoea due to mitral stenosis. Mitral valve replacement was performed and the appearance of the valve was typical of mucopolysaccharide infiltration. Dyspnoea in patients with the Maroteaux-Lamy syndrome may be due primarily to cardiac valve involvement, and in this setting, valve surgery is safe and effective.

Entities:  

Mesh：

Year:  1992        PMID： 1409196      PMCID： PMC2399296          DOI： 10.1136/pgmj.68.798.287

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  6 in total

1.  Gargoylism with cardiovascular involvement in two brothers.

Authors:  R W EMANUEL
Journal:  Br Heart J       Date:  1954-10

2.  The pathology and biochemistry of gargoylism; a report of three cases with a review of the literature.

Authors:  J L HENDERSON; A R MacGREGOR; S J THANNHAUSER; R HOLDEN
Journal:  Arch Dis Child       Date:  1952-06       Impact factor: 3.791

3.  Mucopolysaccharidosis, an unusual cause of cardiac valvular disease.

Authors:  G A Glober; K R Tanaka; J A Turner; C K Liu
Journal:  Am J Cardiol       Date:  1968-07       Impact factor: 2.778

4.  Type 3 mucopolysaccharidosis: report of a case with severe mitral valve involvement.

Authors:  J K Herd; S Subramanian; H Robinson
Journal:  J Pediatr       Date:  1973-01       Impact factor: 4.406

5.  Mucopolysaccharidosis type IV as a cause of mitral stenosis in an adult.

Authors:  M A Ireland; D B Rowlands
Journal:  Br Heart J       Date:  1981-07

6.  Cardiac manifestations of the mucopolysaccharidoses.

Authors:  R M Schieken; R E Kerber; V V Ionasescu; H Zellweger
Journal:  Circulation       Date:  1975-10       Impact factor: 29.690
  6 in total
  5 in total

Review 1.  Surgical Management of Valvular Heart Disease in Mucopolysaccharidoses: A Review of Literature.

Authors:  Barbara A Rosser; Calvin Chan; Andreas Hoschtitzky
Journal:  Biomedicines       Date:  2022-02-04

2.  Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy.

Authors:  E Braunlin; H Rosenfeld; C Kampmann; J Johnson; M Beck; R Giugliani; N Guffon; D Ketteridge; C M Sá Miranda; M Scarpa; I V Schwartz; E Leão Teles; J E Wraith; P Barrios; E Dias da Silva; G Kurio; M Richardson; G Gildengorin; J J Hopwood; M Imperiale; A Schatz; C Decker; P Harmatz
Journal:  J Inherit Metab Dis       Date:  2012-06-05       Impact factor: 4.982

Review 3.  Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.

Authors:  Elizabeth A Braunlin; Paul R Harmatz; Maurizio Scarpa; Beatriz Furlanetto; Christoph Kampmann; James P Loehr; Katherine P Ponder; William C Roberts; Howard M Rosenfeld; Roberto Giugliani
Journal:  J Inherit Metab Dis       Date:  2011-07-09       Impact factor: 4.982

4.  Anesthesia in a child with Maroteaux-Lamy syndrome undergoing mitral valve replacement.

Authors:  Cem Sayilgan; Lale Yuceyar; Sedat Akbas; Hulya Erolcay
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 5.  Pre-operative Considerations in Adult Mucopolysaccharidosis Patients Planned for Cardiac Intervention.

Authors:  Benjamin Cross; Karolina M Stepien; Chaitanya Gadepalli; Ahmed Kharabish; Peter Woolfson; Govind Tol; Petra Jenkins
Journal:  Front Cardiovasc Med       Date:  2022-04-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.